Company Website:
http://www.ljpc.com
SAN DIEGO -- (Business Wire)
La
Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or
“La Jolla”), a leader in the development of therapeutics targeting
significant unmet life-threatening diseases, today announced the closing
of its underwritten public offering of 5,395,000 shares of common stock
at a public offering price of $10.50 per share, which includes the
partial exercise of the underwriters’ option to purchase up to an
additional 720,000 shares of common stock. Gross offering proceeds are
approximately $56.6 million, including proceeds from the partial
exercise of the underwriters’ option to purchase additional shares,
before deducting customary underwriting discounts and commissions and
offering expenses.
La Jolla intends to use the net proceeds from the offering for general
corporate purposes, including funding its ongoing and future clinical
trials, and for general and administrative expenses.
Jefferies LLC acted as sole book-runner for the offering. Chardan
Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC
and Noble Financial Group, Inc. acted as co-managers for the offering.
The securities described above were offered pursuant to a shelf
registration statement (File No. 333-197092), including a base
prospectus, which was declared effective by the United States Securities
and Exchange Commission (“SEC”) on July 11, 2014. The specific terms of
the offering are described in a prospectus supplement filed with the SEC
in connection with the offering. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state
or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities
laws of any such state or other jurisdiction. The offering was made only
by means of the prospectus supplement and accompanying prospectus,
copies of which may be obtained at the SEC’s website at www.sec.gov,
or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022,
telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.
Contacts:
La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President
& Chief Executive Officer
(858) 207-4264
gtidmarsh@ljpc.com
or
Chester
S. Zygmont, III
Director of Finance
(858) 207-4262
czygmont@ljpc.com
Source: La Jolla Pharmaceutical Company
© 2024 Canjex Publishing Ltd. All rights reserved.